Article

Type 2 Diabetes Is a Risk Factor for Peptic Ulcer Bleeding

Researchers in Taiwan report that type 2 diabetes is independently associated with increased risk of peptic ulcer bleeding.

Noting that some studies have shown patients with diabetes have a higher incidence of peptic ulcer disease, the authors of “Diabetes Is an Independent Risk Factor for Peptic Ulcer Bleeding : A Nationwide Population-Based Cohort Study,” published in the Journal of Gastroenterology and Hepatology, analyzed the medical records of a cohort of patients with type 2 diabetes to determine if they have a higher risk of developing peptic ulcer bleeding and to identify possible risk factors for peptic ulcer bleeding in this population.

For the study, researchers used the National Health Insurance Research Database of Taiwan to identify 5,699 patients with type 2 diabetes and 11,226 age- and sex-matched healthy patients and compared them to “a cohort dataset of 1,000,000 randomly sampled subjects.” They analyzed the cumulative hazard of peptic ulcer bleeding between the two groups, evaluated independent risk factors for peptic ulcer bleeding in all patients in the study, and identified risk factors of peptic ulcer bleeding in patients with type 2 diabetes.

Investigators reported that, in a seven-year follow-up period, patients with type 2 diabetes “had significantly higher cumulative hazard” of peptic ulcer bleeding than controls. After adjusting for age, sex, comorbidities, and use of ulcer medication, the researchers found that diabetes was independently associated with increased risk of peptic ulcer bleeding.

Age, chronic renal disease, history of peptic ulcer disease, and use of non-steroidal anti-inflammatory drugs (NSAIDs) were identified as risk factors for peptic ulcer bleeding in patients with type 2 diabetes.

Based on these results, the authors concluded that patients with type 2 diabetes have “significantly higher risk” of peptic ulcer bleeding, “even after adjustments for possible confounding factors like age, sex, underlying co-morbidities, and ulcerogenic medication.”

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Christine Frissora, MD | Credit: Weill Cornell
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.